Review
doi: 10.1159/000281694.
Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview
Affiliations
- PMID: 2190404
- DOI: 10.1159/000281694
Item in Clipboard
Review
Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview
Urol Int.
1990.
Abstract
Since 1976 superficial bladder cancer is treated with intravesical instillations of Bacillus Calmette-Guérin (BCG). The results with BCG are superior to other intravesical chemotherapeutics, both in superficial tumors and carcinoma in situ. BCG probably acts as a nonspecific potentiator of the immune system. Comparative studies have to give information about the effectiveness and side effects of the different strains of BCG, and about the best clinical schedule. Toxicity is mild in 95% of the cases. Severe side effects and antituberculous drugs are discussed.
Similar articles
-
Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.J Urol. 1991 Apr;145(4):738-40. doi: 10.1016/s0022-5347(17)38439-2. J Urol. 1991. PMID: 2005691 Clinical Trial.
-
Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.J Urol. 1988 May;139(5):935-40. doi: 10.1016/s0022-5347(17)42722-4. J Urol. 1988. PMID: 3361667
-
[Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder tumors: effect of intravesical BCG on papillary tumors].Nihon Hinyokika Gakkai Zasshi. 1986 Oct;77(10):1623-30. doi: 10.5980/jpnjurol1928.77.10_1623. Nihon Hinyokika Gakkai Zasshi. 1986. PMID: 3820900 Japanese. No abstract available.
-
Bacillus Calmette-Guérin immunotherapy. Techniques and results.Urol Clin North Am. 1992 Aug;19(3):557-64. Urol Clin North Am. 1992. PMID: 1636239 Review.
-
[Progression and recurrence in the prostate and upper urinary tract following intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].Nihon Hinyokika Gakkai Zasshi. 1993 Dec;84(12):2146-51. doi: 10.5980/jpnjurol1989.84.2146. Nihon Hinyokika Gakkai Zasshi. 1993. PMID: 8309122 Review. Japanese.
Cited by
-
Sending a Message: Use of mRNA Vaccines to Target the Tumor Immune Microenvironment.Vaccines (Basel). 2023 Sep 7;11(9):1465. doi: 10.3390/vaccines11091465. Vaccines (Basel). 2023. PMID: 37766141 Free PMC article. Review.
-
Intravesical drug delivery. Pharmacokinetic and clinical considerations.Clin Pharmacokinet. 1999 Jul;37(1):59-73. doi: 10.2165/00003088-199937010-00004. Clin Pharmacokinet. 1999. PMID: 10451783 Review.
-
BCG vaccine in urinary bladder cancer.West J Med. 1991 Dec;155(6):633. West J Med. 1991. PMID: 1812634 Free PMC article. No abstract available.
-
Comparisons of Intravesical Treatments with Mitomycin C, Gemcitabine, and Docetaxel for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: Updated Systematic Review and Meta-Analysis.Cancers (Basel). 2024 Dec 10;16(24):4125. doi: 10.3390/cancers16244125. Cancers (Basel). 2024. PMID: 39766024 Free PMC article. Review.
-
Current recommendations for the management of bladder cancer. Drug therapy.Drugs. 1997 Mar;53(3):404-14. doi: 10.2165/00003495-199753030-00005. Drugs. 1997. PMID: 9074842 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
